September 3, 2020

Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

Category: Article Summary

Topic: Vaccines and Immunity

Keywords (Tags): treatment

• NVX-CoV2373, a recombinant nanoparticle vaccine, induced higher levels of anti-spike IgG and neutralizing antibody responses compared to convalescent serum of mostly symptomatic COVID-19 patients. There were no serious adverse events, and events such as fever and sore arm were mild and not long-lasting. These results were from a primary analysis at day 35 of a randomized control trial (n=83). [EDITORIAL NOTE: A summary of a pre-print version of this manuscript appeared in the Lit Rep on August 6]

Keech et al. (Sept 2, 2020). Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2026920